Audrey Lau

2.3k total citations
41 papers, 1.0k citations indexed

About

Audrey Lau is a scholar working on Epidemiology, Hepatology and Immunology. According to data from OpenAlex, Audrey Lau has authored 41 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Epidemiology, 21 papers in Hepatology and 16 papers in Immunology. Recurrent topics in Audrey Lau's work include Hepatitis B Virus Studies (20 papers), Hepatitis C virus research (16 papers) and Immunotherapy and Immune Responses (10 papers). Audrey Lau is often cited by papers focused on Hepatitis B Virus Studies (20 papers), Hepatitis C virus research (16 papers) and Immunotherapy and Immune Responses (10 papers). Audrey Lau collaborates with scholars based in United States, Italy and Canada. Audrey Lau's co-authors include Angus W. Thomson, Masanori Abe, Anuj Gaggar, Holger Hackstein, An De Creus, G. Mani Subramanian, Giorgio Raimondi, Maurizia Rossana Brunetto, Carlo Ferrari and Sang Hoon Ahn and has published in prestigious journals such as The Journal of Immunology, Gastroenterology and Hepatology.

In The Last Decade

Audrey Lau

40 papers receiving 996 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Audrey Lau United States 16 559 451 383 117 108 41 1.0k
Kouzaburo Yamaji Japan 14 403 0.7× 394 0.9× 177 0.5× 81 0.7× 66 0.6× 27 758
A Uhrig Germany 8 319 0.6× 395 0.9× 562 1.5× 163 1.4× 182 1.7× 10 1.0k
Vincent Leroy France 17 813 1.5× 828 1.8× 307 0.8× 49 0.4× 48 0.4× 37 1.1k
Niclas Thomas United Kingdom 11 273 0.5× 179 0.4× 385 1.0× 133 1.1× 111 1.0× 15 780
Axel Ulsenheimer Germany 17 851 1.5× 955 2.1× 482 1.3× 144 1.2× 66 0.6× 28 1.5k
Robert C. Tam United States 17 477 0.9× 553 1.2× 339 0.9× 231 2.0× 75 0.7× 28 1.2k
Elisavet Serti United States 15 516 0.9× 598 1.3× 466 1.2× 100 0.9× 116 1.1× 24 1.1k
Maria Quasdorff Germany 13 718 1.3× 510 1.1× 179 0.5× 267 2.3× 51 0.5× 20 1.0k
Akinobu Takaki Japan 10 545 1.0× 741 1.6× 176 0.5× 65 0.6× 52 0.5× 36 918
Linsheng Guo United States 13 1.0k 1.8× 1.0k 2.3× 94 0.2× 168 1.4× 254 2.4× 15 1.5k

Countries citing papers authored by Audrey Lau

Since Specialization
Citations

This map shows the geographic impact of Audrey Lau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Audrey Lau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Audrey Lau more than expected).

Fields of papers citing papers by Audrey Lau

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Audrey Lau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Audrey Lau. The network helps show where Audrey Lau may publish in the future.

Co-authorship network of co-authors of Audrey Lau

This figure shows the co-authorship network connecting the top 25 collaborators of Audrey Lau. A scholar is included among the top collaborators of Audrey Lau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Audrey Lau. Audrey Lau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cornberg, Markus, Pietro Lampertico, Soo Aleman, et al.. (2025). Improvement in liver histology is observed in most patients with chronic hepatitis delta after 48 weeks of bulevirtide monotherapy. Zeitschrift für Gastroenterologie. 63. 1 indexed citations
2.
Feld, Jordan J., Henry Lik‐Yuen Chan, Teerha Piratvisuth, et al.. (2025). Association of Metabolic Comorbidities With Fibrosis Severity and Fibrosis Regression in Patients With Chronic Hepatitis B. Clinical Gastroenterology and Hepatology. 24(1). 121–130.e12. 1 indexed citations
3.
Asselah, Tarik, Pietro Lampertico, Soo Aleman, et al.. (2024). Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48. Liver International. 45(4). e16174–e16174. 5 indexed citations
4.
Cheung, Bob, Jik Chang Leong, Edwin Chan, et al.. (2024). Evaluating the effects of inorganic UV filter titanium dioxide nanoparticles (nano-TiO2) on early life stages of scleractinian coral Acropora tumida. Marine Pollution Bulletin. 209(Pt B). 117231–117231.
5.
6.
7.
Agarwal, Kosh, Sang Hoon Ahn, Audrey Lau, et al.. (2018). Safety and efficacy of vesatolimod (GS‐9620) in patients with chronic hepatitis B who are not currently on antiviral treatment. Journal of Viral Hepatitis. 25(11). 1331–1340. 71 indexed citations
8.
Gane, Edward, Hyung Joon Kim, Kumar Visvanathan, et al.. (2018). Safety, Pharmacokinetics and Pharmacodynamics of Oral TLR8 Agonist GS-9688 in Patients with Chronic Hepatitis B: A Randomized, Placebo-Controlled, Double-Blind Phase 1b Study. Hepatology. 68. 2 indexed citations
9.
Boni, Carolina, Andrea Vecchi, Marzia Rossi, et al.. (2018). TLR7 Agonist Increases Responses of Hepatitis B Virus–Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues. Gastroenterology. 154(6). 1764–1777.e7. 112 indexed citations
10.
Janssen, Harry L.A., Maurizia Rossana Brunetto, Yoon Jun Kim, et al.. (2017). Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. Journal of Hepatology. 68(3). 431–440. 142 indexed citations
11.
Krams, Sheri M., Steven Schaffert, Audrey Lau, & Olivia M. Martinez. (2016). Applying Mass Cytometry to the Analysis of Lymphoid Populations in Transplantation. American Journal of Transplantation. 17(8). 1992–1999. 13 indexed citations
12.
Wei, Liang, Xiaoxing Xiong, Audrey Lau, et al.. (2016). Absence of miR-182 Augments Cardiac Allograft Survival. Transplantation. 101(3). 524–530. 15 indexed citations
13.
Vitalone, Matthew J., Wei Liang, Masato Fujiki, et al.. (2016). Liver microRNA Profile of Induced Allograft Tolerance. Transplantation. 100(4). 781–790. 14 indexed citations
14.
Perito, Emily R., Audrey Lau, Sue Rhee, John P. Roberts, & Philip Rosenthal. (2012). Posttransplant metabolic syndrome in children and adolescents after liver transplantation: A systematic review. Liver Transplantation. 18(9). 1009–1028. 34 indexed citations
15.
Lau, Audrey, Kyle Soltys, Rakesh Sindhi, et al.. (2010). Chronic high Epstein-Barr viral load carriage in pediatric small bowel transplant recipients. Pediatric Transplantation. 14(4). 549–553. 62 indexed citations
16.
Lau, Audrey, Gyöngyi Szabó, & Angus W. Thomson. (2008). Antigen-presenting cells under the influence of alcohol. Trends in Immunology. 30(1). 13–22. 36 indexed citations
17.
Creus, An De, Masanori Abe, Audrey Lau, et al.. (2005). Low TLR4 Expression by Liver Dendritic Cells Correlates with Reduced Capacity to Activate Allogeneic T Cells in Response to Endotoxin. The Journal of Immunology. 174(4). 2037–2045. 122 indexed citations
18.
Bell, Sally, Audrey Lau, A. Thompson, et al.. (2004). Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients. Journal of Clinical Virology. 32(2). 122–127. 23 indexed citations
19.
Lau, Audrey, et al.. (2003). Liver tolerance mediated by antigen presenting cells: fact or fiction?. Gut. 52(8). 1075.1–1078. 28 indexed citations
20.
Lau, Audrey. (2003). Dendritic cells and immune regulation in the liver. Gut. 52(2). 307–314. 128 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kouzaburo Yamaji Breakdown of academic impact, for papers by A Uhrig Breakdown of academic impact, for papers by Vincent Leroy Breakdown of academic impact, for papers by Niclas Thomas Breakdown of academic impact, for papers by Axel Ulsenheimer Breakdown of academic impact, for papers by Robert C. Tam Breakdown of academic impact, for papers by Elisavet Serti Breakdown of academic impact, for papers by Maria Quasdorff Breakdown of academic impact, for papers by Akinobu Takaki Breakdown of academic impact, for papers by Linsheng Guo
Rankless by CCL
2026